In 2006, a phase III trial evaluating temsirolimus in combination with endocrine therapy (letrozole) in estrogen receptor-positive (ER+) women with advanced breast cancer was discontinued due to missed endpoints involving efficacy [56,57]. This evidence concerns the gene ESR1 and breast cancer.